E1v1.11

N/A

Report date: 2025/03/19 08:58:06
NME

Base Information

Drug NameE1v1.11
Drug Alias NameE1MOv11SMN2 Element 1 antisense oligonucleotide therapy (Shift Pharmaceuticals)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionAntisense oligonucleotide inhibitorsSMN2 gene modulatorsNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsMuscular Atrophy, Spinal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Missouri
China Registration ClassN/A

Develop Information

Active CompaniesShift Pharmaceuticals LLC
Inactive CompaniesUniversity Of Missouri
Active IndicationsMuscular Atrophy, Spinal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A